We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A recent statement by Brazil's Trade Minister, Pedro Furlan, has highlighted major international generics makers' growing interest in Latin American markets.
Drugmakers present on the fast-growing Polish market have welcomed a likely reduction in VAT on registered medicines, but it still remains unclear which products will now escape the previous rate of 22%.
According to Australia's Health Insurance Commission, prescriptions for drugs supplied under the country's Pharmaceutical Benefits Scheme(PBS) have fallen in the wake of recent price rises.
Millennium Pharmaceuticals Inc. said it agreed to sell additional rights to its Integrilin heart drug to Schering-Plough Corp. in return for $35.5 million in cash and at least $170 million in royalties.
Pharmaceuticals retailer and manufacturer Australian Pharmaceutical Industries Ltd (ASX:API) is looking to expand its retail-based strategy into products for the elderly.
Takeda Pharmaceutical (TSE: 4502) announced on July 14 that it has agreed with Pharmaceutical Product Development (PPD), a US pharmaceutical company, concerning rights to the dipeptidyl peptidase IV (DPP4) inhibitor.
Nihon Pharmaceuticals Industry (NPI), a joint venture between Ranbaxy Laboratories and Nippon Chemiphar (NC), has launched its first, co-developed product Vogseal 0.2mg & 0.3mg tablets (generic Voglibose) in Japan.
Teva Pharmaceutical Industries Ltd. agreed to buy Ivax Corp. of the U.S. Monday in a $7.4 billion cash-and-stock deal that will restore the Israeli company's No. 1 position in the market for generic medicines.